Watching PHIBRO ANIMAL HEALTH CORP? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planPHIBRO ANIMAL HEALTH CORP
AI Executive Summary
AI-powered analysis of 10-K filing content
Phibro Animal Health's FY2026 10-K reflects a company that successfully integrated the ~$297.5 million Zoetis medicated feed additive (MFA) acquisition, which contributed $358.2 million in net sales for the year, up from $208.2 million in the partial prior year period. The company maintains effective internal controls and disclosure controls with a clean audit opinion, though it carries elevated debt from acquisition financing and continues to face concentrated geographic and geopolitical exposures in Brazil, Israel, and the Middle East. No material weaknesses, restatements, or going concern issues were identified.
Red Flags Detected (6)
Acquisition of Zoetis MFA portfolio ($297.5M) was funded entirely by term loan borrowings under a new/amended 2024 Credit Agreement, increasing leverage
Executive Chairman Jack Bendheim's entity (BFI Co., LLC) adopted a 10b5-1 plan to sell up to 750,000 Class A shares through March 2027, signaling potential insider liquidity/diversification
Continued material exposure to Brazil (12% of consolidated assets and net sales) subject to currency, political and economic volatility
3 more red flags detected
Key Takeaways
Zoetis MFA acquisition is a significant growth driver, nearly doubling its revenue contribution year-over-year ($208.2M to $358.2M)
Company operates ~790 product lines across ~90 countries and ~4,800 customers, indicating diversified but livestock-concentrated revenue base
3 more takeaways
Filing Overview
What This Means
Annual Report: Comprehensive filing covering the full fiscal year with audited financial statements.